Published in Hepatology on March 01, 2006
Clinical features and management of primary biliary cirrhosis. World J Gastroenterol (2008) 0.85
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08
Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
A large set of Finnish affected sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 11, and 14. Diabetes (2004) 2.46
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol (2008) 1.69
Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol (2004) 1.66
AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology (2013) 1.64
Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc (2011) 1.62
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet (2010) 1.62
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Noninvasive assessment of liver fibrosis. Hepatology (2011) 1.57
Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. J Gastroenterol (2013) 1.55
Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. Liver Int (2010) 1.54
Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53
"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology (2013) 1.35
Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.33
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet (2012) 1.32
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
Abdominal magnetic resonance elastography. Top Magn Reson Imaging (2009) 1.26
The genetics of complex cholestatic disorders. Gastroenterology (2013) 1.24
Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet (2014) 1.21
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol (2010) 1.17
Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging (2011) 1.14
The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol (2007) 1.13
Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology (2008) 1.11
Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol (2012) 1.09
Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease. AJR Am J Roentgenol (2011) 1.09
Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol (2006) 1.07
Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol (2007) 1.05
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis. Gastroenterology (2006) 1.00
Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol (2010) 0.99
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol (2007) 0.99
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol (2007) 0.98
Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. Abdom Imaging (2015) 0.98
Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int (2013) 0.97
Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology (2008) 0.93
Primary biliary cirrhosis is associated with a genetic variant in the 3' flanking region of the CTLA4 gene. Gastroenterology (2008) 0.92
Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2013) 0.92
Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am (2011) 0.91
Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol (2013) 0.90
Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl (2004) 0.89
Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology (2011) 0.89
Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing. Cancer Cytopathol (2014) 0.88
Update on the genetics and genomics of PBC. J Autoimmun (2010) 0.88
Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl (2012) 0.87
Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management. Clin Liver Dis (2012) 0.87
Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am (2006) 0.87
Novel de novo heterozygous FGFR1 mutation in two siblings with Hartsfield syndrome: a case of gonadal mosaicism. Am J Med Genet A (2014) 0.86
Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol (2013) 0.86
Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol (2006) 0.86
Genetics and genomics of primary biliary cirrhosis. Clin Liver Dis (2008) 0.86
Hepatic and splenic stiffness augmentation assessed with MR elastography in an in vivo porcine portal hypertension model. J Magn Reson Imaging (2013) 0.86
Primary biliary cirrhosis. Best Pract Res Clin Gastroenterol (2010) 0.86
Genomics in the post-GWAS era. Semin Liver Dis (2011) 0.86
Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. J Am Acad Dermatol (2006) 0.84
Genomics and complex liver disease: Challenges and opportunities. Hepatology (2006) 0.84
Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl (2013) 0.83
Common genetic variation and haplotypes of the anion exchanger SLC4A2 in primary biliary cirrhosis. Am J Gastroenterol (2009) 0.83
Applying genomics to the study of complex disease. Semin Liver Dis (2007) 0.83
Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology (2010) 0.82
Questionnaire based assessment of risk factors for primary biliary cirrhosis. Dig Liver Dis (2013) 0.82
Time trends in hospitalization and discharge status for cirrhosis and portal hypertension in the United States. Hepatology (2010) 0.82
Risk of lymphoma in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2007) 0.82
Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver Int (2014) 0.81
The AmpliChip CYP450 test: principles, challenges, and future clinical utility in digestive disease. Clin Gastroenterol Hepatol (2006) 0.80
Celiac disease-associated autoimmune cholangitis. Am J Gastroenterol (2002) 0.80
Clinical management of autoimmune biliary diseases. J Autoimmun (2013) 0.80
Cholestatic liver disease. Med Clin North Am (2013) 0.79
Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl (2012) 0.78
Methodologic issues with transfer of ultrasound-based transient elastography into clinical practice. J Hepatol (2007) 0.78
Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. J Thorac Oncol (2015) 0.78
Economic impact of hospitalization for end-stage liver disease. Am J Gastroenterol (2002) 0.78
One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis. Hepatology (2009) 0.78
Genetics of hepatobiliary diseases. Clin Gastroenterol Hepatol (2006) 0.77
MR Elastography of Liver Disease: State of the Art. Appl Radiol (2013) 0.77
Chronic inflammation, liver stiffness, and clinical decision making: an unavoidable partnership. Clin Gastroenterol Hepatol (2012) 0.77
Acute graft-versus-host disease after liver transplantation. Transplantation (2007) 0.77
Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 0.76
Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep (2013) 0.76
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci (2009) 0.76
Predicting clinical outcomes with elastography in primary biliary cirrhosis: one step closer? Gastroenterology (2013) 0.76
Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol (2017) 0.75
Practice variation in treatment of primary biliary cirrhosis and effect on clinical outcomes. Hepatology (2008) 0.75
Role of computerized image morphometry for assessing noninvasive methods to detect hepatic fibrosis. Clin Gastroenterol Hepatol (2008) 0.75
Recognizing and preventing death from compensated cirrhosis in the community. Liver Int (2011) 0.75
Functional hepatic imaging and disease recurrence after liver transplantation. Liver Transpl (2006) 0.75
Quantitative dynamic contrast-enhanced magnetic resonance imaging for assessing treatment response in hepatocellular carcinoma. Gastroenterology (2008) 0.75
Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis. Liver Int (2008) 0.75
Determining the nature and impact of fatigue after liver transplantation. Liver Transpl (2006) 0.75